EASL DAY 1
EASL DAY 2
EASL DAY 3
EASL DAY 1
Thursday Aug 27, 2020
Our Surfers Discussed The Following Papers and Sessions on Day 1
Louise Campbell MSc AP — Session Patients for nonalcoholic fatty liver disease referred from primary care have a significant serum fibrosis marker and liver stiffness measurement discordance.
and
AS160: Multidisciplinary team approach to nonalcoholic fatty liver disease improves cardiovascular risk factors
Surfing The NASH Tsunami Podcast Day 1
EASL DAY 2
Friday Aug 28, 2020
Our Surfers Will Discuss The Following Papers and Sessions on Day 2
Sonic Incytes is on a mission to reduce chronic liver disease by enabling routine assessment and management of liver health. Its breakthrough, point of care ultrasound solution, Velacur™, assesses and manages chronic liver disease with diagnostic accuracy that is comparable to MRI. Learn more: www.sonicincytes.com
EASL DAY 3